

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

lisdexamfetamine chewable tablets (Vyvanse)

Notes:

- Quantity Limits: Yes
- Adequate trial of a long acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.

Initiation (new start) criteria: Non-formulary **lisdexamfetamine chewable tablets (Vyvanse)** will be covered on the prescription drug benefit when the following criteria are met:

For Binge Eating Disorder:

- Diagnosis of Binge Eating Disorder **-AND-**
- Prior adequate trial (6 weeks) and failure of 2 formulary Selective Serotonin Reuptake Inhibitors (SSRIs) unless contraindication, intolerance, or allergy **-AND-**
- Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansules), unless allergy to an inactive ingredient or history of substance use disorder **-OR-**
- Patient is already stable on drug

For attention-deficit/hyperactivity disorder (ADHD) or attention deficit disorder (ADD) in patients under 21 years of age:

- Diagnosis of ADHD or ADD **-AND-**
- Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansules), unless allergy to an inactive ingredient or history of substance use disorder **-OR-**
- Patient is already stable on drug.

For patients 21 years of age or older not currently taking Vyvanse chewable tablets:

- Diagnosis of ADHD or ADD **-AND-**
- Adequate trial** (7 days) of a methylphenidate product (methylphenidate or dexmethylphenidate) **-AND-**
- Adequate trial** (7 days) of amphetamine salt combo, unless allergy to an inactive ingredient **-AND-**
- Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansules), unless allergy to an inactive ingredient **-OR-**
- Past diagnosis or treatment for substance use disorder

kp.org

Revised: 01/13/22
Effective: 03/03/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

lisdexamfetamine chewable tablets (Vyvanse)

For patients 21 years of age or older currently taking Vyvanse chewable tablets:

- Diagnosis of ADHD or ADD **-AND-**
- Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansules), unless allergy to an inactive ingredient or history of substance use disorder
- **-OR-**
- Dose change only: patient meets current criteria and is already taking the drug

kp.org

Revised: 01/13/22
Effective: 03/03/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest